Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsRanbaxylaboratories

    Stock analysis is used by traders to make buy and sell call. It’s an approach to make informed decisions while investing in stocks. Stock analysis can be categorised into – fundamental analysis and technical analysis. Fundamental analysis is evaluation of data from sources, including financial records, economic reports, company assets, and market share. Analysts typically study the company’s financial statements – balance sheet, income statement, cash flow statement, and footnotes. These statements are made available to the investors in the form of quarterly earnings, disclosures to stock exchanges in compliance with the Securities and Exchange Board of India (Sebi) norms. In fundamental analysis, the analysts particularly check for a company's core income, income from other sources, profitability, guidance, assets and liabilities and debt ratio among other parameters. The other method, i.e. the technical analysis focuses purely on statistical data. It works on two assumptions; one, the stock price reflects the fundamentals. Second, the study of past and present movement in prices can help determine the future price trends. Technical analysis primarily deals with price, volume, demand and supply factors. This method is effective only when supply and demand forces influence the market. However, when outside factors are involved in a price movement, technical analysis may not be successful. More

    Jump to
    • Initiate long position in Ranbaxy Laboratories: Chaturmohta

      Initiate long position in Ranbaxy Laboratories: Chaturmohta

      Ashish Chaturmohta of Fortune Equity Broker is of the view that one may go long in Ranbaxy Laboratories as the stock may test Rs 485-490.

    • Bullish on Lupin, Aurobindo; cautious on Ranbaxy: Religare

      Bullish on Lupin, Aurobindo; cautious on Ranbaxy: Religare

      Arvind Bothra, vice president of institutional research at Religare Capital Markets is cautious on Ranbaxy because the earnings visibility is very low and believes that the expectations of a turnaround in the US business etc are seemingly priced-in the stock.

    • Buy Ranbaxy Labs for long term: Navneet Daga

      Buy Ranbaxy Labs for long term: Navneet Daga

      Navneet Daga of KR Choksey Securities recommends buying Ranbaxy Laboratories for long term as the stock may test Rs 500.

    • Hold Glenmark, Cipla; prefer HCL Tech, KPIT: Deven Choksey

      Hold Glenmark, Cipla; prefer HCL Tech, KPIT: Deven Choksey

      According to Deven Choksey, MD of KR Choksey Shares and Securities, one can prefer HCL Technologies and KPIT Technologies within the IT space and Glenmark Pharma and Cipla from pharma space.

    • Sell Ranbaxy Laboratories: Sriram Rathi

      Sell Ranbaxy Laboratories: Sriram Rathi

      Sriram Rathi, pharma analyst at Anand Rath recommends selling Ranbaxy Laboratories with a target of Rs 375.

    • USFDA nod will aid Ranbaxy's sentiment, not revenue: Expert

      USFDA nod will aid Ranbaxy's sentiment, not revenue: Expert

      The USFDA today approved Ranbaxy‘s drug called Plendil generic, which is used for hypertension. Ranbaxy was expected to be the authorised generic for this particular drug, but it is already genericised and there are already 6-7 players in this market for this particular drug.

    • Buy Ranbaxy Laboratories at current levels: Sukhani

      Buy Ranbaxy Laboratories at current levels: Sukhani

      Sudarshan Sukhani of s2analytics.com recommends buying Ranbaxy Laboratories at current levels.

    • Buy United Breweries, Ranbaxy; sell JSW Energy: SP Tulsian

      Buy United Breweries, Ranbaxy; sell JSW Energy: SP Tulsian

      SP Tulsian of sptulsian.com recommends going long in United Breweries with a target of Rs 800 and advises selling Oriental Bank of Commerce with a target of Rs 209.

    • Go long in Ranbaxy, advises Ashish Chaturmohta

      Go long in Ranbaxy, advises Ashish Chaturmohta

      Ashish Chaturmohta of Fortune Equity Brokers recommends going long in Ranbaxy Laboratories with a target of Rs 490 and a stoploss at Rs 435.

    • Hold Ranbaxy, it may test Rs 170-490: Nooresh Merani

      Hold Ranbaxy, it may test Rs 170-490: Nooresh Merani

      Nooresh Merani of AMSEC is of the view that one may hold Ranbaxy Laboratories.

    • Buy Ranbaxy Labs 450 Call: Krish Subramanyam

      Buy Ranbaxy Labs 450 Call: Krish Subramanyam

      Krish Subramanyam of Asit C Mehta Investment is of the view that one may buy Ranbaxy Laboratories 450 strike Call.

    • Buy Ranbaxy Laboratories: Sudarshan Sukhani

      Buy Ranbaxy Laboratories: Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com recommends buying Ranbaxy Laboratories as the stock may test Rs 455-460 in the short term.

    • Rakesh Arora positive on Ranbaxy Laboratories

      Rakesh Arora positive on Ranbaxy Laboratories

      Rakesh Arora of Macquarie Capital Securities has a positive view on Ranbaxy Laboratories.

    • Go long on Ranbaxy Laboratories: Ashish Chaturmohta

      Go long on Ranbaxy Laboratories: Ashish Chaturmohta

      Ashish Chaturmohta of Fortune Equity Brokers recommends going long in Ranbaxy Laboratories with a target of Rs 450 and a stoploss at Rs 403.

    • Stay away from capital goods, metal space: Sukhani

      Stay away from capital goods, metal space: Sukhani

      Sudarshan Sukhani of s2analytics.com advises to stay away from capital goods and metal space.

    • Buy Reliance Capital, Ranbaxy: Manas Jaiswal

      Buy Reliance Capital, Ranbaxy: Manas Jaiswal

      Manas Jaiswal of manasjaiswal.com is of the view that one may buy Reliance Capital at current levels with a stop loss of Rs 363.

    • Ranbaxy Laboratories may go to Rs 430-432: SP Tulsian

      Ranbaxy Laboratories may go to Rs 430-432: SP Tulsian

      SP Tulsian of sptulsian.com is positive on Ranbaxy Laboratories and may go to Rs 430-432 in the near term.

    • Sell Ranbaxy Laboratories, says Rajesh Agarwal

      Sell Ranbaxy Laboratories, says Rajesh Agarwal

      Rajesh Agarwal, Director - Research at Eastern Financiers Limited advises selling Ranbaxy Laboratories and buying Lupin with a target of Rs 1,015 in the next 9-12 months.

    • Buy Ranbaxy Labs, Apollo Tyres; sell JSW Steel: SP Tulsian

      Buy Ranbaxy Labs, Apollo Tyres; sell JSW Steel: SP Tulsian

      SP Tulsian of sptulsian.com recommends going long on Ranbaxy Laboratories with a target of Rs 405 and advises selling Adani Enterprises with a target of Rs 199-200.

    • Ranbaxy Laboratories may test Rs 375: Sriram Rathi

      Ranbaxy Laboratories may test Rs 375: Sriram Rathi

      According to Sriram Rathi of Anand Rathi, one may buy Ranbaxy Laboratories with a long term perspective.

    • Buy Ranbaxy, RComm; sell Century Textiles: SP Tulsian

      Buy Ranbaxy, RComm; sell Century Textiles: SP Tulsian

      SP Tulsian of sptulsian.com recommends going long on Ranbaxy Laboratories with a day target of Rs 399 and Shriram Transport Finance Corporation with a day target of Rs 620.

    • Avoid pharma space, says Nilesh Shah

      Avoid pharma space, says Nilesh Shah

      Nilesh Shah, MD & CEO at Envision Capital advises to avoid pharmaceutical space.

    • Avoid Ranbaxy Laboratories, advises Sudarshan Sukhani

      Avoid Ranbaxy Laboratories, advises Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com is of the view that one may avoid Ranbaxy Laboratories.

    • Buy Ranbaxy Laboratories, advises Salil Sharma

      Buy Ranbaxy Laboratories, advises Salil Sharma

      Salil Sharma of Kapur Sharma & Co recommends buying Ranbaxy Laboratories as the stock may test Rs 412 in the short term.

    • Expect 50% returns in Ranbaxy Laboratories: Rajen Shah

      Expect 50% returns in Ranbaxy Laboratories: Rajen Shah

      According to Rajen Shah of Angel Stock Broking, one may see 50 percent returns in Ranbaxy Laboratories over the next 12-18 months.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347